New drug for diabetics could end ordeal of daily insulin jabs (Daily Mail, 25 January 2010)

26 Jan 2010


Novo Nordisk has announced that it is about to commence clinical trials on an oral form of Victoza, a glucagon-like peptide. Victoza has been approved for the treatment of type 2 diabetes but its license is currently limited to an injectable form.

Full article


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story